Advertisement
Australia markets closed
  • ALL ORDS

    7,837.40
    -100.10 (-1.26%)
     
  • ASX 200

    7,575.90
    -107.10 (-1.39%)
     
  • AUD/USD

    0.6553
    +0.0030 (+0.46%)
     
  • OIL

    83.78
    +0.21 (+0.25%)
     
  • GOLD

    2,358.90
    +16.40 (+0.70%)
     
  • Bitcoin AUD

    98,271.11
    +931.52 (+0.96%)
     
  • CMC Crypto 200

    1,389.89
    -6.64 (-0.48%)
     
  • AUD/EUR

    0.6095
    +0.0022 (+0.36%)
     
  • AUD/NZD

    1.0983
    +0.0025 (+0.23%)
     
  • NZX 50

    11,805.09
    -141.34 (-1.18%)
     
  • NASDAQ

    17,430.50
    -96.30 (-0.55%)
     
  • FTSE

    8,108.29
    +29.43 (+0.36%)
     
  • Dow Jones

    38,085.80
    -375.12 (-0.98%)
     
  • DAX

    18,044.18
    +126.90 (+0.71%)
     
  • Hang Seng

    17,651.15
    +366.61 (+2.12%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

Is AbbVie Stock a Buy Now?

Is AbbVie Stock a Buy Now?

Given the volatility of AbbVie's (NYSE: ABBV) stock over the past year, it's pretty clear that traders are worried about next year's impending Humira patent cliff. Although the way AbbVie is going, an earnings slump is likely to be short-lived. Humira was seen as a blockbuster from the beginning; the rheumatoid arthritis medication brought in $800 million in its first full year of sales in 2003, back when AbbVie was still part of Abbott Laboratories.